Target Information
| Target General Infomation | Top | ||||
|---|---|---|---|---|---|
| Target ID |
T89879
|
||||
| Target Name |
SARS-CoV RNA-directed RNA polymerase (RdRp)
|
||||
| Synonyms |
SARS-CoV RNA-directed RNA polymerase; SARS-CoV Pol; SARS-CoV RdRp; SARS-CoV nsp12 polymerase
|
||||
| Gene Name |
SARS-CoV rep; SARS-CoV 1a-1b
|
||||
| Target Status |
Target in Preclinical Study
|
[1] | |||
| Disease | [+] 1 Target-related Diseases | + | |||
| 1 | Severe acute respiratory syndrome [ICD-11: 1D65] | ||||
| Function |
Responsible for replication and transcription of the viral RNA genome.
|
||||
| BioChemical Class |
Coronaviruses polyprotein 1ab family
|
||||
| UniProt ID | |||||
| EC Number |
EC 2.7.7.48
|
||||
| Sequence |
SADASTFLNRVCGVSAARLTPCGTGTSTDVVYRAFDIYNEKVAGFAKFLKTNCCRFQEKD
EEGNLLDSYFVVKRHTMSNYQHEETIYNLVKDCPAVAVHDFFKFRVDGDMVPHISRQRLT KYTMADLVYALRHFDEGNCDTLKEILVTYNCCDDDYFNKKDWYDFVENPDILRVYANLGE RVRQSLLKTVQFCDAMRDAGIVGVLTLDNQDLNGNWYDFGDFVQVAPGCGVPIVDSYYSL LMPILTLTRALAAESHMDADLAKPLIKWDLLKYDFTEERLCLFDRYFKYWDQTYHPNCIN CLDDRCILHCANFNVLFSTVFPPTSFGPLVRKIFVDGVPFVVSTGYHFRELGVVHNQDVN LHSSRLSFKELLVYAADPAMHAASGNLLLDKRTTCFSVAALTNNVAFQTVKPGNFNKDFY DFAVSKGFFKEGSSVELKHFFFAQDGNAAISDYDYYRYNLPTMCDIRQLLFVVEVVDKYF DCYDGGCINANQVIVNNLDKSAGFPFNKWGKARLYYDSMSYEDQDALFAYTKRNVIPTIT QMNLKYAISAKNRARTVAGVSICSTMTNRQFHQKLLKSIAATRGATVVIGTSKFYGGWHN MLKTVYSDVETPHLMGWDYPKCDRAMPNMLRIMASLVLARKHNTCCNLSHRFYRLANECA QVLSEMVMCGGSLYVKPGGTSSGDATTAYANSVFNICQAVTANVNALLSTDGNKIADKYV RNLQHRLYECLYRNRDVDHEFVDEFYAYLRKHFSMMILSDDAVVCYNSNYAAQGLVASIK NFKAVLYYQNNVFMSEAKCWTETDLTKGPHEFCSQHTMLVKQGDDYVYLPYPDPSRILGA GCFVDDIVKTDGTLMIERFVSLAIDAYPLTKHPNQEYADVFHLYLQYIRKLHDELTGHML DMYSVMLTNDNTSRYWEPEFYEAMYTPHTVLQ |
||||
| Drugs and Modes of Action | Top | ||||
|---|---|---|---|---|---|
| Preclinical Drugs | [+] 2 Preclinical Drugs | + | |||
| 1 | PMID31244113-compound-2c | Drug Info | Preclinical | SARS | [1] |
| 2 | Galidesivir | Drug Info | Preclinical | SARS | [2] |
| Investigative agents | [+] 2 Investigative agents | + | |||
| 1 | Ribavirin | Drug Info | Investigative | SARS | [2], [3] |
| 2 | Remdesivir | Drug Info | Investigative | SARS | [4] |
| Mode of Action | [+] 1 Modes of Action | + | |||
| Inhibitor | [+] 4 Inhibitor drugs | + | |||
| 1 | Remdesivir | Drug Info | [4] | ||
| 2 | Galidesivir | Drug Info | [2] | ||
| 3 | Ribavirin | Drug Info | [2], [3] | ||
| 4 | PMID31244113-compound-2c | Drug Info | [1] | ||
| References | Top | ||||
|---|---|---|---|---|---|
| 1 | Design, Synthesis, and Anti-RNA Virus Activity of 6'-Fluorinated-Aristeromycin Analogues. J Med Chem. 2019 Jul 11;62(13):6346-6362. | ||||
| 2 | Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. | ||||
| 3 | SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016 Aug;14(8):523-34. | ||||
| 4 | Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 Jan 10;11(1):222. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.